Skip to main content

Table 4 Characteristics of donor-derived HCV infection in transplant recipients

From: Hepatitis C positive organ transplantation to negative recipients at a multiorgan Canadian transplant centre: ready for prime time

Characteristics

Total (N = 22)

HCV genotype (%)

 1a

13 (59.1)

 1b

2 (9.1)

 2

1 (4.5)

 3

6 (27.3)

Detection HCV viral load (IU/mL)

8.9 × 105 (2.4 × 105—5.9 × 106)

HCV viremia detection interval (%)

 Week 1

17 (77.3)

 Week 2

3 (13.6)

 Week 3

2 (9.1)

Time to start DAA therapy (days)

41.5 (31.0–54.5)

DAA therapy started (%)

22 (100)

DAA therapy (%)

 Sofosbuvir/velpatasvir

10 (45.5)

 Glecaprevir/pibrentasvir

9 (40.9)

 Ledipasvir/sofosbuvir

2 (9.1)

 Elbasvir/grazoprevir

1 (4.5)

SVR4 (%)

21 (95.5)

SVR12 (%)

21 (95.5)*

Adverse events (%)

0 (0)

Graft failure (%)

0 (0)

  1. Data are number of patients (%) or median (IQR)
  2. All patients were treated with 12 weeks of antivirals except for patients with glecaprevir/pibrentasvir that received 8 weeks
  3. *All patients who completed their DAA regimen achieved SVR12 (N = 21). One patient died while on Glecaprevir/Pibrentasvir before finishing the course